Royal Bank Of Canada Reiterates Outperform Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank Of Canada in a research report issued on Tuesday, Digital Look reports. They currently have a £145 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 22.59% from the company’s current price.

Several other research firms have also recently issued reports on AZN. Citigroup lifted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Berenberg Bank reaffirmed a “buy” rating and set a £160 target price on shares of AstraZeneca in a research note on Thursday, September 3rd. Jefferies Financial Group reiterated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Wednesday, September 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of £151.14.

AstraZeneca Trading Down 0.4%

AZN stock opened at £118.28 on Tuesday. AstraZeneca has a 1-year low of £107.84 and a 1-year high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of £183.44 billion, a price-to-earnings ratio of 17.71, a PEG ratio of 0.86 and a beta of 0.20. The business has a 50 day simple moving average of £124.79 and a two-hundred day simple moving average of £136.10.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.